OWise Breast Cancer

Home
United Kingdom
London
OWise Breast Cancer

Download the OWise breast cancer support app for free here: https://owi.se/dl 💜 https://linktr.ee/OWisebreast

04/11/2026

Joint pain on aromatase inhibitors can feel like something is wrong with your joints, but that may not be what’s happening.

Experiencing joint pain while taking aromatase inhibitors such as anastrozole, letrozole or exemestane? 💜

Joint pain is a common side effect of these hormone treatments, but it doesn’t necessarily mean there’s damage to your joints.

Understanding why joint pain happens and what may help can make managing treatment side effects a little easier 🙏

👉 Read our full article to learn more about aromatase inhibitor-related joint pain and ways to manage it 💜 https://owise.uk/aromatase-inhibitors-joint-pain/

03/11/2026

New EU approval for HER2-positive early breast cancer 💜

For people whose HER2-positive breast cancer has not completely disappeared after treatment before surgery, a newly approved treatment could offer better protection against the cancer returning.

💊 Enhertu (trastuzumab deruxtecan)

In the DESTINY-Breast05 trial, Enhertu was compared with Kadcyla (trastuzumab emtansine) after surgery.

🔹 At 3 years, 92.4% of patients receiving Enhertu were alive without invasive breast cancer returning, compared with 83.7% receiving Kadcyla.

🔹 This means Enhertu significantly reduced the risk of invasive cancer recurrence or death compared with Kadcyla.

🇪🇺 In October 2026, the EU approved Enhertu for this post-surgery setting,

🇺🇸 This received FDA approval in the US in May 2026.

🇬🇧 In the UK a NICE appraisal is awaiting development.

These results represent an important advance for people with HER2-positive early breast cancer who still have invasive cancer remaining after treatment before surgery 🙏

Share this update with others who may benefit from knowing about the latest HER2-positive breast cancer treatment options 💜

For more on early HER2+ breast cancer treatment options read this 🔗 https://owise.uk/her2/

03/11/2026

Your treatment plan made sense when it was explained, but now you’re trying to remeber what happens when…😶‍🌫️

Keep your treatment plan in OWise so you can check what comes next📲✨ Download OWise here 🔗 owi.se/dl

02/11/2026

Some of the most meaningful friendships can come from the most unexpected places 💜

In Part 8 of her 15 Things I Wish I Knew When I Was First Diagnosed With Breast Cancer series, Carly reflects on the incredible friendships she made within the cancer community 🙏

Read the full blog here 📖💜 https://owise.uk/15-things-wish-i-had-known-when-i-was-diagnosed-breast-cancer/

31/10/2026

Breast Cancer Awareness Month Series #17: Metastatic TNBC: What Treatment Looks Like Now and What’s Changed 💜

Treatment options for metastatic triple-negative breast cancer (TNBC) have changed significantly in recent years, with new targeted therapies and clinical trial results offering more options for patients 🙏

But which treatments are available and what determines whether someone is eligible?

In the final post of our Breast Cancer Awareness Month series, we’re breaking down:

🔹 What metastatic TNBC means and how it differs from other breast cancer subtypes

🔹 How chemotherapy, immunotherapy, antibody-drug conjugates (ADCs) and PARP inhibitors work

🔹 Why biomarkers such as PD-L1, HER2-low and BRCA mutations can influence treatment decisions

🔹 Recent treatment advances, including Datroway, Trodelvy and Enhertu, and what the latest clinical trials have shown

🔹 Common treatment side effects and ways to manage them

Understanding your cancer’s characteristics and the treatments available can help you have more informed conversations with your care team about your options.

And with that we’ve reached the end of our Breast Cancer Awareness Month series!💜

Thank you for following along and remember all 17 posts are here for you to revisit whenever you need them 🙏

From understanding your diagnosis to managing treatment, OWise is here to support you every step of the way. Download for free here 💜🔗 https://owi.se/dl

30/10/2026

Breast Cancer Awareness Month Series #16: The treatment landscape for metastatic HER2+ breast cancer is changing 💜

New treatments and clinical trial results are expanding the options available for people with metastatic HER2-positive breast cancer, including new first-line treatments and maintenance therapies.

In this post, we’re breaking down:

🔹 What HER2-positive breast cancer means and how HER2 status is tested

🔹 Current treatment options, from HER2-targeted therapies to antibody-drug conjugates (ADCs)

🔹 New treatment approvals and results from the PATINA, DESTINY-Breast09 and HER2CLIMB-05 trials

🔹 Long-term results from DESTINY-Breast03 and what they mean for second-line treatment

🔹 Treatment options for brain and bone metastases

🔹 Common treatment side effects and ways to manage them

Understanding which treatments are available, how they compare and when they may be used can help you have more informed conversations with your care team 🙏

For more detailed information about metastatic HER2-positive breast cancer and its treatments read this 👉 https://owise.uk/her2-secondary-breast-cancer-treatments/

This is post #16 in our Breast Cancer Awareness Month series, where we’re covering breast cancer diagnosis, treatment and beyond throughout October 💜

30/10/2026

Palbociclib: What’s new in 2026?💜

Palbociclib is commonly used in HR+/HER2− breast cancer. In June 2026, the FDA expanded its use to maintenance treatment for HR+/HER2+ locally advanced or metastatic breast cancer💊

What did the PATINA trial find?🔬

1️⃣Palbociclib + trastuzumab, with or without pertuzumab, + hormone therapy👇

🔹HR+/HER2+ locally advanced or metastatic breast cancer that had not progressed after initial chemotherapy and HER2-targeted treatment.

📊 Median time before cancer grew or spread: 44.3 months

2️⃣Trastuzumab, with or without pertuzumab, + hormone therapy👇

🔹For the same patient group, without palbociclib.

📊 Median time before cancer grew or spread: 29.1 months

2026 update🔬

🇺🇸 The FDA approved palbociclib for this new maintenance indication in June 2026.

🇪🇺 The European application for this indication was withdrawn in October 2026.

🏥 The NICE appraisal is awaiting development.

The PATINA trial found that adding palbociclib extended median progression-free survival by 15.2 months compared with HER2-targeted therapy and hormone therapy alone👩‍⚕️✨

Follow for more updates on breast cancer treatments and research💜

28/10/2026

What nobody tells you about the first few weeks after a breast cancer diagnosis🙏

Carly Moosah shares what she wishes she had known in those early days of her triple negative breast cancer diagnosis💜

Read Carly’s blog “Diagnosed with Breast Cancer? What to Expect and How to Cope”📖✨

🔗 https://owise.uk/newly-diagnosed-breast-cancer/

27/10/2026

Breast Cancer Awareness Month Series #15: What’s New in Metastatic HR+ Breast Cancer Treatment in 2026? 💜

How is metastatic HR+ breast cancer treated, and what options are available if your current treatment stops working?

Treatment for HR+/HER2− metastatic breast cancer is changing, with new targeted therapies, drug approvals and clinical trials expanding the options available at different stages of treatment 🙌

In this carousel we’re breaking down:

🔹 First-line treatment: Why hormone therapy combined with a CDK4/6 inhibitor is usually the starting point, and how ESR1 blood testing may help guide an earlier treatment switch.

🔹 If the cancer progresses: How testing for mutations such as ESR1, PIK3CA, AKT1, PTEN and BRCA can help identify which treatments may work next.

🔹 Second- and later-line treatments: The different options available depending on mutation results, including targeted therapies and antibody-drug conjugates (ADCs).

🔹 What’s new: Recent treatment approvals and results from clinical trials including VIKTORIA-1, SERENA-6, EVEra, OptiTROP-02 and ELEVATE.

Understanding how treatment decisions are made, and why your options may change over time, can help you have more informed conversations with your care team 🙏

💬 For more detailed information about metastatic HR+ breast cancer and the treatment options available read this 🔗 https://owise.uk/secondary-hormone-positive/

This is post #15 in our Breast Cancer Awareness Month series, where we’re covering breast cancer diagnosis, treatment and beyond throughout October 💜

26/10/2026

When treatment ends but the worry doesn’t: Understanding fear of recurrence🙏

The fear of recurrence is the worry or concern relating to the possibility that cancer will come back or progress. It’s experienced in 20-50% of breast cancer survivors and most prevalent in the first year of treatment, having a significant impact on everyday life📊👩‍⚕️

Specific situations can trigger feelings of fear, such as:

🔹A doctor’s appointment
🔹Waiting for results
🔹A milestone anniversary
🔹When a family member, friend or public figure is diagnosed or has passed away

Here are some things that may help manage the fear of recurrence👇

✨Be well informed
✨Express your fear
✨Live a healthy lifestyle
✨Seek external support
✨Relieve stress
✨Reflection

‼️If management techniques don’t improve these feelings, it may be time to seek professional help.

Comment ‘Fear’ below and we’ll send you more detailed information💜

Address

London

Website

https://owise.us/, https://owise.us/es/, https://owise.uk/, https://owi.se/dl

Alerts

Be the first to know and let us send you an email when OWise Breast Cancer posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.